Complete Genomics is conducting its customer pilot projects using its existing R&D sequencing instruments. However, the company is also in the process of scaling up its genome center and transitioning to a commercial operation. After its commercial launch in January 2010, Complete Genomics will conduct much larger sequencing projects and employ new commercial-scale instruments that will be able to read well over one terabase (1012 bases) per run.

Complete Genomics will achieve this goal by increasing the efficiency of its technology on multiple levels. The company is building higher-density DNA nanoarrays (DNBs) that will contain 2.85 billion spots of DNA arranged in a grid with 70 bases per spot, allowing it to sequence an entire human genome on a single array. It is also developing new sequencing instruments that will be able to read the sequences from multiple DNA nanoarrays concurrently, thereby sequencing well over one terabase in a single run. These advances will dramatically increase the company ™s sequencing throughput to one instrument-day per genome.

The company ™s high-volume genomic sequencing will naturally generate massive amounts of data, which will be managed and analyzed in its data center using its proprietary software on a high-performance computing cluster.

The key to Complete Genomics ™ success is its sharp focus on providing only complete human genome sequencing in a massively parallel process. By optimizing all of its systems for this one task, the company is strongly positioned to become the dominant supplier of large-scale human genomic data.

completegenomics